Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
about
Optimizing Trial Designs for Targeted Therapies"Threshold-crossing": A Useful Way to Establish the Counterfactual in Clinical Trials?Sample Size Reassessment and Hypothesis Testing in Adaptive Survival TrialsAdaptive designs from a Data Safety Monitoring Board perspective: Some controversies and some case studies.Cross-sector surveys assessing perceptions of key stakeholders towards barriers, concerns and facilitators to the appropriate use of adaptive designs in confirmatory trialsPractical characteristics of adaptive design in phase 2 and 3 clinical trials.Sample size adjustment designs with time-to-event outcomes: A caution.The role of adaptive trial designs in drug development.Many-to-one comparisons after safety selection in multi-arm clinical trials.A modified varying-stage adaptive phase II/III clinical trial design.Accounting for selection and correlation in the analysis of two-stage genome-wide association studies.Authors' response to comments.A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study.Examining Tensions That Affect the Evaluation of Technology in Health Care: Considerations for System Decision Makers From the Perspective of Industry and Evaluators.Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint: Power, time-to-analysis, and operational aspects.Optimized adaptive enrichment designs.Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research.Adaptive designs: The Swiss Army knife among clinical trial designs?Adaptive paediatric investigation plans, a small step to improve regulatory decision making in drug development for children?Critical concepts in adaptive clinical trials.Using Bayesian modeling in frequentist adaptive enrichment designs.Adaptive designs in clinical trials: why use them, and how to run and report them.Lessons learned from IDeAl - 33 recommendations from the IDeAl-net about design and analysis of small population clinical trials.
P2860
Q28554393-7F12E9EE-772C-4538-B69A-9CE194CADA9AQ28595570-23986655-63C7-4909-B76C-F790A02152D9Q35919624-218020A1-AFC0-447B-828C-AD1C955D305AQ36274426-06C4DD29-41C3-4ACC-A6B5-B114D491ACE8Q36402269-4054A700-0884-46EE-B246-E804FDDB44DEQ38603746-3903AC33-744D-4ABB-9350-48A69FA35970Q38630899-717CC8BC-62DA-446E-82EE-E55802E267A1Q38691922-60609409-546D-450F-AF60-919E1B7144AEQ38708697-5E868435-81B3-4D0F-AFE2-44A3846E7607Q39708750-6F4E5831-06D5-4CD3-8065-86B11C1B9BA0Q40844820-66F45029-334B-4ABF-8A61-8B204DD4447DQ40983087-5490C552-5DCC-4921-A21F-8FBFD791754AQ41638122-8513B5B9-3B30-4CC9-BC9B-6DC3377E4EA3Q47112017-69E15C24-D576-4B91-A68B-E4C82576B705Q47387422-BA5009A1-0788-41FD-BBC8-D43471B02753Q47574086-FAFC1A13-95CB-4D6D-84F4-8AAE6906C5C7Q47625359-4194410E-8833-4311-BDDF-699FC46A8C39Q47856748-A3DB9E44-ADE5-43DF-9505-D1E077D08D23Q50499560-2C835FFF-1DAA-45F3-BF8C-F8182DD836D7Q52335056-BF2126B4-98DA-4A04-83CA-59B70E574098Q52646325-F273BF6C-D7C0-4337-9722-404051C7DED3Q52681001-D45CBB18-7400-4A14-88EA-EFC1DE38561EQ54941922-202BC882-9183-4076-8770-C98A9BE2F474
P2860
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
@en
type
label
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
@en
prefLabel
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls.
@en
P2093
P2860
P356
P1476
Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls
@en
P2093
Gernot Wassmer
Peter Bauer
Vladimir Dragalin
P2860
P304
P356
10.1002/SIM.6472
P407
P577
2015-03-16T00:00:00Z